<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="case-report">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">XWv5ZVZTKsJwCrbVZQTh9Jt</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2012001500017</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(12)09900600017</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2012001500017</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Relato de Caso</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Intera&#231;&#227;o multidisciplinar em cardiologia invasiva: alcooliza&#231;&#227;o septal</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ybarra</surname>
            <given-names>Luiz Fernando</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pereira</surname>
            <given-names>Diego Roberto Barbosa</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Manh&#227;es</surname>
            <given-names>Eduardo</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fernandes</surname>
            <given-names>Fabio</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vieira</surname>
            <given-names>Marcelo Luiz Campos</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lemos</surname>
            <given-names>Pedro Alves</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">SP</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina </institution>
        <institution content-type="orgdiv2">Hospital das Cl&#237;nicas</institution>
        <country country="BR">Brasil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>12</month>
        <year>2012</year>
      </pub-date>
      <volume>99</volume>
      <issue>6</issue>
      <fpage>e174</fpage>
      <lpage>e177</lpage>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <pub-date publication-format="electronic" date-type="pub">
        <day>11</day>
        <month>03</month>
        <year>2013</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>RELATO DE CASO</bold>
    </p>
    <p>
      <bold>Intera&#231;&#227;o multidisciplinar em cardiologia invasiva: alcooliza&#231;&#227;o septal</bold>
    </p>
    <p>
      <bold>Luiz Fernando Ybarra; Diego Roberto Barbosa Pereira; Eduardo Manh&#227;es; Fabio Fernandes; Marcelo Luiz Campos Vieira; Pedro Alves Lemos</bold>
    </p>
    <p>Instituto do Cora&#231;&#227;o do Hospital das Cl&#237;nicas da Faculdade de Medicina da Universidade de S&#227;o Paulo (Incor/HCFMUSP), S&#227;o Paulo, SP - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="end">Correspond&#234;ncia</xref>
    </p>
    <p><bold>Palavras-chave: </bold>Cardiomiopatia Hipertr&#243;fica; Hipertrofia Ventricular Esquerda; Ecocardiografia Transesof&#225;gica; T&#233;cnicas de Abla&#231;&#227;o.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A Cardiomiopatia Hipertr&#243;fica (CMH) &#233; uma doen&#231;a heredit&#225;ria autoss&#244;mica dominante, caracterizada por hipertrofia ventricular, cuja preval&#234;ncia na popula&#231;&#227;o geral &#233; de 1:500<sup>1</sup>. A obstru&#231;&#227;o na via de sa&#237;da do ventr&#237;culo esquerdo incide em 25% dos casos e &#233; marcador de pior progn&#243;stico. Ocorre devido &#224; combina&#231;&#227;o de fatores mec&#226;nicos e hemodin&#226;micos, tais como: hipertrofia do septo interventricular, contra&#231;&#227;o hiperdin&#226;mica do ventr&#237;culo esquerdo e movimento anterior sist&#243;lico da c&#250;spide anterior da valva mitral<sup>2</sup>. Em pacientes refrat&#225;rios ao tratamento medicamentoso, a Abla&#231;&#227;o Septal Alco&#243;lica percut&#226;nea (ASA) pode ser indicada como estrat&#233;gia para reduzir a obstru&#231;&#227;o. A associa&#231;&#227;o da Ecocardiografia Transesof&#225;gica (ETE) durante a alcooliza&#231;&#227;o elevou o sucesso do procedimento para cerca de 90%<sup>1</sup>. </p>
    <p>Neste artigo, relatamos um caso de CMH septal assim&#233;trica tratada com ASA auxiliada pelo ETE tridimensional, seguido pela revis&#227;o da literatura e discuss&#227;o cr&#237;tica da intera&#231;&#227;o e envolvimento da cardiologia invasiva com diversos outros especialistas da medicina como a abordagem ideal para tal tipo de procedimento.</p>
    <p>
      <bold>Relato do Caso</bold>
    </p>
    <p>Paciente masculino, 31 anos, hipertenso com hist&#243;ria de CMH assim&#233;trica diagnosticada h&#225; 6 anos. Apresentava antecedente familiar de CMH e morte s&#250;bita, tendo seu pai realizado cirurgia para corre&#231;&#227;o da hipertrofia septal. Foi admitido com queixa de dispneia ao repouso (classe funcional IV - NYHA), associada &#224; ortopneia e dispneia parox&#237;stica noturna. Estava em uso de atenolol 100 mg/dia, verapamil 160 mg/dia e furosemida 80 mg/dia. No exame f&#237;sico, foi evidenciado sopro sist&#243;lico ejetivo padr&#227;o crescendo e decrescendo em foco a&#243;rtico acess&#243;rio.</p>
    <p>Durante investiga&#231;&#227;o diagn&#243;stica h&#225; 4 anos, a resson&#226;ncia magn&#233;tica card&#237;aca mostrou presen&#231;a de hipertrofia ventricular esquerda com predom&#237;nio septal determinando obstru&#231;&#227;o de via de sa&#237;da, al&#233;m de insufici&#234;ncia mitral e de realce tardio mioc&#225;rdico focal em parede anterosseptal, compat&#237;vel com fibrose na jun&#231;&#227;o ventricular. A espessura da parede septal anterior era de 11 mm e da lateral posterior de 14 mm. </p>
    <p>Na admiss&#227;o, foi realizado um ecocardiograma que evidenciou ventr&#237;culo esquerdo com desempenho sist&#243;lico hiperdin&#226;mico, sem altera&#231;&#245;es da mobilidade segmentar e com padr&#227;o restritivo, septo ventricular de 19 mm, parede posterior do ventr&#237;culo esquerdo de 14 mm, di&#226;metro diast&#243;lico e sist&#243;lico do ventr&#237;culo esquerdo de 47 e 26 mm, respectivamente, e valva mitral com movimento sist&#243;lico anterior da c&#250;spide anterior. O gradiente sist&#243;lico m&#225;ximo intraventricular foi estimado em 92 mmHg. </p>
    <p>Devido &#224; persist&#234;ncia de sintomas limitantes na vig&#234;ncia de tratamento medicamentoso pleno, optou-se pela ASA para al&#237;vio dos sintomas. O procedimento foi realizado com aux&#237;lio do ETE tridimensional, que demonstrava gradiente intraventricular de 104 mmHg no in&#237;cio do procedimento (<xref ref-type="fig" rid="a17fig01">Figura 1</xref>).</p>
    <p content-type="asset">
      <fig id="a17fig01">
        <graphic xlink:href="1678-4170-abc-99-06-e174-00017-gf01.jpg"/></fig>
    </p>
    <p>Alguns autores preconizam a abla&#231;&#227;o septal atrav&#233;s da cateteriza&#231;&#227;o seletiva do maior ramo septal (neste caso, o 2&#186; ramo septal - <xref ref-type="fig" rid="a17fig02">Figura 2</xref>), respons&#225;vel pela irriga&#231;&#227;o da por&#231;&#227;o m&#233;dio-basal do septo interventricular, conforme observado ap&#243;s a inje&#231;&#227;o de contraste ecogr&#225;fico, seguindo-se a infus&#227;o lenta de &#225;lcool absoluto<sup>1,2</sup>. Contudo, em nosso caso, tanto ap&#243;s a oclus&#227;o do ramo quanto ap&#243;s a infus&#227;o de &#225;lcool, n&#227;o se observou diminui&#231;&#227;o do gradiente. Ante a aus&#234;ncia de resultado efetivo, procedeu-se &#224; procura de outro ramo com potencial efeito terap&#234;utico. Apesar do reduzido calibre e comprimento, a cateteriza&#231;&#227;o do 1&#186; ramo septal com oclus&#227;o por cateter-bal&#227;o resultou em queda do gradiente ao ETE tridimensional associado &#224; redu&#231;&#227;o septal, os quais foram restaurados ao aspecto basal ap&#243;s a desinsufla&#231;&#227;o do bal&#227;o. Al&#233;m disto, a inje&#231;&#227;o de contraste ecogr&#225;fico demonstrou uma maior &#225;rea de irriga&#231;&#227;o da por&#231;&#227;o m&#233;dio-basal do septo interventricular do 1&#186; ramo septal quando comparado ao 2&#186;. Com base nesses achados, procedemos &#224; alcooliza&#231;&#227;o com 2 ml do 1&#186; septal, com redu&#231;&#227;o do gradiente intraventricular pela manometria invasiva para 21 mmHg e pelo ETE tridimensional para 26 mmHg, sem complica&#231;&#245;es.</p>
    <p content-type="asset">
      <fig id="a17fig02">
        <graphic xlink:href="1678-4170-abc-99-06-e174-00017-gf02.jpg"/></fig>
    </p>
    <p>Ap&#243;s 3 dias da interven&#231;&#227;o, um novo ecocardiograma foi realizado e evidenciou septo ventricular de 16 mm, gradiente da via de sa&#237;da do ventr&#237;culo esquerdo de 46 mmHg e melhora da altera&#231;&#227;o diast&#243;lica (padr&#227;o pseudonormal). O paciente evoluiu est&#225;vel hemodinamicamente e assintom&#225;tico, recebendo alta ap&#243;s quatro dias em uso de atenolol 50 mg por dia.</p>
    <p>No retorno de um m&#234;s, o paciente queixou-se de um epis&#243;dio de dor precordial ao repouso seguida de s&#237;ncope, sendo aumentado o atenolol para 100 mg ao dia. No seguimento de quatro meses, apresentava-se assintom&#225;tico.</p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>O principal achado deste relato de caso &#233; que a melhor t&#233;cnica de ASA envolve a intera&#231;&#227;o de m&#250;ltiplos profissionais das diversas &#225;reas da cardiologia e da medicina dedicados a este tipo de interven&#231;&#227;o.</p>
    <p>A alcooliza&#231;&#227;o inicial do grande ramo septal n&#227;o resultou na melhora hemodin&#226;mica esperada, conforme prontamente identificado pelo ETE. Logo em seguida, a identifica&#231;&#227;o morfol&#243;gica de outro alvo terap&#234;utico pela angiografia (1&#186; ramo septal) foi confirmada como de funcionamento importante pelo ETE, possibilitando sucesso do procedimento.</p>
    <p>Tipicamente, o primeiro grande ramo septal acess&#237;vel &#233; identificado pela angiografia e selecionado para abla&#231;&#227;o<sup>1,2</sup>. No entanto, imagens ecocardiogr&#225;ficas durante o procedimento podem sugerir a alcooliza&#231;&#227;o de outro ramo, conforme a localiza&#231;&#227;o da fibrose septal provocada durante o procedimento. O ETE tridimensional se destaca em tal contexto ao auxiliar na identifica&#231;&#227;o correta da art&#233;ria respons&#225;vel pela hipertrofia septal, e, assim, evitar a alcooliza&#231;&#227;o de ramos que irriguem o m&#250;sculo papilar ou a parede livre do ventr&#237;culo direito<sup>3</sup>. </p>
    <p>A anestesia geral &#233; utilizada com frequ&#234;ncia, proporcionando maior seguran&#231;a durante o procedimento. Esta &#233; aconselh&#225;vel especialmente quando exista risco de instabilidade cardiorrespirat&#243;ria durante o procedimento. O anestesista deve conhecer as peculiaridades dos procedimentos cardiol&#243;gicos invasivos e, em particular, da ASA, pois a manipula&#231;&#227;o do cateter, cateter-bal&#227;o, cordas-guias e do &#225;lcool podem provocar eventos agudos.</p>
    <p>O bloqueio atrioventricular completo &#233; uma complica&#231;&#227;o que apresenta resolu&#231;&#227;o espont&#226;nea na maioria dos casos em at&#233; 13 dias, sendo que menos de 10% necessitam de marca-passo definitivo, principalmente se a interven&#231;&#227;o &#233; auxiliada pelo ecocardiograma<sup>1,3-5</sup>. O infarto agudo do mioc&#225;rdio transmural, com forma&#231;&#227;o de &#225;reas potencialmente arritmog&#234;nicas, e a comunica&#231;&#227;o interventricular s&#227;o outras poss&#237;veis complica&#231;&#245;es. Dependem, fundamentalmente, do tamanho da &#225;rea de necrose provocada pela quantidade de &#225;lcool injetada. A utiliza&#231;&#227;o das imagens ecogr&#225;ficas durante o procedimento mostrou-se eficaz em localizar o melhor local para inje&#231;&#227;o alco&#243;lica, tamb&#233;m reduzindo tais complica&#231;&#245;es<sup>1-3</sup>.</p>
    <p>O epis&#243;dio de s&#237;ncope p&#243;s-procedimento pode ter ocorr&#234;ncia secund&#225;ria &#224; arritmia, uma vez que o paciente apresentava antecedente familiar de morte s&#250;bita e realce tardio mioc&#225;rdico focal na resson&#226;ncia magn&#233;tica, podendo ser candidato a implante de cardioversor-desfibrilador implant&#225;vel. </p>
    <p>Ainda n&#227;o est&#225; bem definido na literatura se a alcooliza&#231;&#227;o septal percut&#226;nea da CMH septal assim&#233;trica altera o progn&#243;stico do paciente. Contudo, sua qualidade de vida, representada por melhora dos sintomas e da capacidade de exerc&#237;cio, seguramente aumenta<sup>1,2</sup>. Tal melhora p&#244;de ser observada no presente caso, estando o paciente assintom&#225;tico e com apenas uma &#250;nica medica&#231;&#227;o ap&#243;s quatro meses do procedimento.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="end" fn-type="corresp">
        <label>
          <bold> Correspond&#234;ncia:</bold>
        </label>
        <p> Luiz Fernando Ybarra </p>
        <p> Rua Peixoto Gomide, 1653, Apto 142, Jardim Paulista </p>
        <p> CEP 01409-003, S&#227;o Paulo, SP - Brasil </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="lfybarra@gmail.com">lfybarra@gmail.com</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 05/10/11; revisado em 05/10/11; aceito em 10/04/12.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <mixed-citation>1.	Rigopoulos AG, Seggewiss H. A decade of percutaneous septal ablation in hypertrophic cardiomyopathy. Circ J. 2011;75(1):28-37.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A decade of percutaneous septal ablation in hypertrophic cardiomyopathy</article-title>
          <source>Circ J</source>
          <date>
            <year>2011</year>
          </date>
          <fpage>28</fpage>
          <lpage>37</lpage>
          <issue>1</issue>
          <volume>75</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rigopoulos</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Seggewiss</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation>2.	Fifer MA, Sigwart U. Controversies in cardiovascular medicine. Hypertrophic obstructive cardiomyopathy: alcohol septal ablation. Eur Heart J. 2011;32(9):1059-64.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Controversies in cardiovascular medicine: Hypertrophic obstructive cardiomyopathy: alcohol septal ablation</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2011</year>
          </date>
          <fpage>1059</fpage>
          <lpage>64</lpage>
          <issue>9</issue>
          <volume>32</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fifer</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Sigwart</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation>3.	Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation. 1998;98(22):2415-21.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography</article-title>
          <source>Circulation</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>2415</fpage>
          <lpage>21</lpage>
          <issue>22</issue>
          <volume>98</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Faber</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Seggewiss</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gleichmann</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation>4.	Chen AA, Palacios IF, Mela T, Yoerger DM, Picard MH, Vlahakes G, et al. Acute predictors of subacute complete heart block after alcohol septal ablation for obstructive hypertrophic cardioyopathy. Am J Cardiol. 2006;97(2):264-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Acute predictors of subacute complete heart block after alcohol septal ablation for obstructive hypertrophic cardioyopathy</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>264</fpage>
          <lpage>9</lpage>
          <issue>2</issue>
          <volume>97</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Palacios</surname>
              <given-names>IF</given-names>
            </name>
            <name>
              <surname>Mela</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yoerger</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Picard</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Vlahakes</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation>5.	Reinhard W, Ten Cate FJ, Scholten M, De Laat LE, Vos J. Permanent pacing for complete atrioventricular block after nonsurgical (alcohol) septal reduction in patients with obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2004;93(8):1064-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Permanent pacing for complete atrioventricular block after nonsurgical (alcohol) septal reduction in patients with obstructive hypertrophic cardiomyopathy</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1064</fpage>
          <lpage>6</lpage>
          <issue>8</issue>
          <volume>93</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Reinhard</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Ten Cate</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Scholten</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>De Laat</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Vos</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Multidisciplinary interaction in invasive cardiology: septal alcoholization</article-title>
      </title-group>
    </front-stub>
    <body>
      <p>
        <bold>CASE REPORT</bold>
      </p>
      <p>
        <fn id="enda-body2">
          <label>
            <bold>Multidisciplinary interaction in invasive cardiology: septal alcoholization</bold>
          </label>
          <p>
            <bold>Luiz Fernando Ybarra; Diego Roberto Barbosa Pereira; Eduardo Manh&#227;es; Fabio Fernandes; Marcelo Luiz Campos Vieira; Pedro Alves Lemos</bold>
          </p>
        </fn>
      </p>
      <p>Instituto do Cora&#231;&#227;o do Hospital das Cl&#237;nicas da Faculdade de Medicina da Universidade de S&#227;o Paulo (Incor/HCFMUSP), S&#227;o Paulo, SP - Brasil</p>
      <p>Mailing Address</p>
      <p><bold>Keywords: </bold>Cardiomyopathy, Hypertrophic; Hypertrophy, Left Ventricular; Echocardiography, Transesophageal; Ablation Techniques.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disease characterized by ventricular hypertrophy whose prevalence in the general population is 1:500<sup>1</sup>. Obstruction of the left ventricular outflow tract occurs in 25% of cases and is a marker of poor prognosis. It occurs due to a combination of mechanical and hemodynamic factors, such as interventricular septal hypertrophy, hyperdynamic left ventricular contraction and systolic anterior motion of the anterior cusp of the mitral valve<sup>2</sup>. In patients refractory to medical therapy, percutaneous alcohol septal ablation (ASA) may be indicated as a strategy to reduce obstruction. The association of transesophageal echocardiography (TEE) during alcoholization has increased the procedural success to approximately 90%<sup>1</sup>. </p>
      <p>We report a case of asymmetric septal HCM treated with ASA guided by three-dimensional TEE, followed by literature review and critical discussion of the interaction and involvement of invasive cardiology with several other medical specialists as the ideal approach for this type of procedure. </p>
      <p>
        <bold>Case Report</bold>
      </p>
      <p>A 31-year-old male patient with hypertension and a history of asymmetric HCM diagnosed 6 years earlier. He had a family history of HCM and sudden death and his father had undergone surgery for correction of septal hypertrophy. On admission, he complained of dyspnea at rest (NYHA class IV), associated with orthopnea and paroxysmal nocturnal dyspnea. He was on atenolol 100 mg/day, verapamil 160 mg/day and furosemide 80 mg/day. On physical examination, a systolic ejection murmur with a waxing and waning pattern was observed in the aortic area. </p>
      <p>During the diagnostic investigation four years earlier, cardiac magnetic resonance imaging had shown the presence of left ventricular hypertrophy with septal predominance, which determined outflow tract obstruction, in addition to mitral regurgitation and focal myocardial delayed enhancement in the anteroseptal wall, consistent with fibrosis at the ventricular junction. The anterior septal wall thickness was 11 mm and the posterior lateral wall thickness was 14 mm. </p>
      <p>On admission, an echocardiogram was performed, which showed a left ventricle with hyperdynamic systolic performance, with no alterations in segmental motion or restrictive pattern, 19-mm ventricular septum, 14-mm LV posterior wall, diastolic and systolic left ventricular diameter of 47 and 26 mm, respectively, and mitral valve with anterior systolic motion of the anterior cusp. The peak intraventricular systolic gradient was estimated at 92 mmHg.</p>
      <p>Due to the persistence of limiting symptoms throughout optimized drug treatment, we chose to perform ASA aiming at symptom relief. The procedure was performed using three-dimensional TEE, which showed an intraventricular gradient of 104 mmHg at the beginning of the procedure (<xref ref-type="fig" rid="en_a17fig01-body2">Figure 1</xref>).</p>
      <p content-type="asset">
        <fig id="en_a17fig01-body2">
          <graphic xlink:href="1678-4170-abc-99-06-e174-00017-gf01-en.jpg"/></fig>
      </p>
      <p>Some authors advocate septal ablation by selective catheterization of the largest septal branch (in this case, the 2<sup>nd</sup> septal branch - <xref ref-type="fig" rid="en_a17fig02-body2">Figure 2</xref>), which is responsible for the irrigation of the mid-basal portion of the interventricular septum, as observed after echographic contrast injection, followed by slow infusion of absolute alcohol<sup>1,2</sup>. However, in this case, after both occlusion of the branch and alcohol infusion, there was no decrease in the gradient. In view of the lack of effective results, we searched for another branch with therapeutic potential. Despite the reduced caliber and length, catheterization of the 1<sup>st</sup> septal branch with balloon-catheter occlusion resulted in gradient decrease, observed at the three-dimensional transesophageal echocardiography, associated with septal reduction, which was restored to the basaline aspect after balloon deflation. Moreover, the injection of echographic contrast showed a larger irrigation area of the mid-basal portion of the interventricular septum of the 1<sup>st</sup> septal branch, when compared to the 2<sup>nd</sup>. Based on these findings, we performed alcoholization of the 1<sup>st</sup> septal branch with 2 mL, with reduction of the intraventricular gradient, as observed by invasive manometry, to 21 mmHg and by three-dimensional TEE to 26 mmHg, with no complications. </p>
      <p content-type="asset">
        <fig id="en_a17fig02-body2">
          <graphic xlink:href="1678-4170-abc-99-06-e174-00017-gf02-en.jpg"/></fig>
      </p>
      <p>After three days of intervention, a new echocardiogram was performed and disclosed a ventricular septum of 16 mm, LV outflow tract gradient of 46 mmHg and improvement of the diastolic alteration (pseudonormal pattern). The patient was hemodynamically stable and asymptomatic, and was discharged four days later, using atenolol 50 mg a day.</p>
      <p>At the 30-day follow-up visit, the patient complained of an episode of chest pain at rest followed by syncope, and the atenolol dose was increased to 100 mg daily. At the four-month follow-up visit he was asymptomatic.</p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>The main finding of this case report is that the best ASA technique involves the interaction of multiple professionals from different fields of Cardiology and Medicine dedicated to this type of intervention. </p>
      <p>The initial alcoholization of the large septal branch did not result in the expected hemodynamic improvement, as readily identified by TEE. Soon after, the morphological identification of another therapeutic target by angiography (1<sup>st</sup> septal branch) was confirmed as functionally important by the TEE, allowing a successful procedure. </p>
      <p>Typically, the first accessible major septal branch is identified by angiography and selected for ablation<sup>1,2</sup>. However, echocardiographic images during the procedure may suggest the alcoholization of another branch, according to the location of the septal fibrosis caused during the procedure. Three-dimensional TEE stands out in this context to help in correct identification of the artery responsible for septal hypertrophy, thus avoiding alcoholization of branches that irrigate the papillary muscle or the RV free wall<sup>3</sup>.</p>
      <p>General anesthesia is often used, allowing greater safety during the procedure. This is especially advisable when there is risk of cardiac instability during the procedure. The anesthesiologist must be aware of the peculiarities of invasive cardiological procedures, and particularly of ASA, since the manipulation of the catheter, balloon catheters, guide wires and alcohol can cause acute events. </p>
      <p>Complete atrioventricular block is a complication that resolves spontaneously in most cases within 13 days, with less than 10% requiring a permanent pacemaker, mainly if the intervention is guided by echocardiography<sup>1,3-5</sup>. Transmural myocardial infarction, with the formation of potentially arrhythmogenic areas, and ventricular septal defect are other possible complications. Basically, they depend on the size of necrosis caused by the injected amount of alcohol. The use of echographic images during the procedure was effective in locating the best site to inject alcohol, as well as in reducing such complications<sup>1-3</sup>. </p>
      <p>The syncope episode after the procedure may have occurred secondary to arrhythmia, as the patient had a family history of sudden death and focal myocardial delayed enhancement on magnetic resonance imaging and he might be eligible to an implantable cardioverter-defibrillator. </p>
      <p>It is yet to be defined in the literature whether percutaneous septal alcoholization of asymmetric septal HCM can alter patient prognosis. However, their quality of life, represented by symptom relief and increased exercise capacity, certainly improves<sup>1,2</sup>. This improvement was observed in the present case, since the patient is asymptomatic and used only one type of medication four months after the procedure.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
